CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

December 31, 2003

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG

CC-8490

Trial Locations (1)

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00074243 - CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas | Biotech Hunter | Biotech Hunter